

Date-22/07/2025

TO,
NSE LIMITED
EXCHANGE PLAZA, 5TH FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.

SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Clarification to Queries Raised by the Exchange – Financial Results for the Year Ended 31/03/2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in response to your observations regarding the financial results submitted for the year ended 31st March 2025, we wish to submit the following point-wise clarification.

We had submitted the audited financial results for the year ended 31st March 2025 on 28th May 2025. Based on your review, the following points were raised, to which we hereby respond:

- 1. Financial results submitted is not as per format prescribed by SEBI-** With reference to NSE Circular No. NSE/CML/2024/23 dated September 05, 2024, regarding the disclosure for utilization of issue proceeds for listed entities on the NSE EMERGE platform. The required disclosure, as per the prescribed format, is attached herewith for your reference and records.
- 2. Segment details not submitted for Consolidated Results:** We would like to clarify that the Company operates in a single business segment. Accordingly, segment-wise reporting is not applicable to the consolidated financial results as per applicable accounting standards.

Request you to consider our above explanation and take the above on your records, if you require any further information regarding the same we will ready to provide you.

Yours faithfully,

FOR, INFINIUM PHARMACHEM LIMITED

**SANJAYKUMAR VITHTHALBHAI PATEL
MANAGING DIRECTOR
DIN: 00370715**

ASHOK RAJPARA & CO
Chartered Accountants

Certificate

Disclosure for utilization of issue proceeds as on 31.03.2025

Pursuant to Regulation 32(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as 'listing regulations'), given below is the statement of utilization of funds of M/s. **Infinium Pharmachem Limited** having their registered office at 38 G I D C Sojitra Taluka: Sojitra Dist: Anand, Sojitra, Gujarat, India 387240 for the year ended 31st March, 2025.

(Rs. In Lacs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Un-utilised Amount	Remarks
1	Registrations, Reach - Europe, other marketing expenses	113.15	113.15	-	
2	Repayment of Existing loans	391.88	391.88	-	
3	Expansion of Existing Unit-2	505.00	249.5	255.50	
4	Incremental working capital	1010.29	1010.29	-	
5	General corporate purpose	443.00	443.00	-	
6	Public Issue expenses	62.40	62.40	-	
Total		2525.72	2270.22	255.50	

PREFERENTIAL ISSUE

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Un-utilised Amount	Remarks
1	Capital expenditure towards expansion or new Projects or to meet working capital requirement. Investment in subsidiary company M/s Infinium Healthcare Pvt Ltd or the purposes of development of existing and new projects, either in the form of equity / quasi equity / unsecured loan Funding Joint Venture and Collaborations as a part of backward integration strategy.	4110.32	1929.99	2180.33	

FOR, ASHOK RAJPARA & CO
Chartered Accountants

Arajpara

(Ashok M. Rajpara)
Proprietor

Membership No. 100559

UDIN : 25100559BMNYAA6209

Date: 28/05/2025

Place : Surat

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS